Peptides DB
Research-centric peptide and protocol reference hub
Study 8 of 38SS-31 literaturebiorxiv-preprint · Case report2023

Adult-Onset Still’s Disease – Still a Diagnostic Dilemma: A Case Report

This case emphasizes the need to consider adult-onset Still's disease in patients with unexplained fever and extremely high ferritin levels, highlighting the importance of early diagnosis and treatment.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the ss-31 corpus
4
Preclinical
26
Observational · this one
0
Open-label
3
Randomised
5
Reviews

Summary and findings

This case report details a 31-year-old male diagnosed with adult-onset Still's disease (AOSD) who presented with extreme hyperferritinemia (>16,000 ng/mL) and systemic inflammation. Initial treatment involved intravenous methylprednisolone 1 mg/kg daily for 5 days, followed by Tocilizumab 162 mg subcutaneously once weekly due to persistent disease activity, resulting in significant clinical and biochemical improvement. No therapeutic claims are made.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
>16,000 ng/mL hyperferritinemian=12023

Abstract

The authors’ words, as biorxiv-preprint supplied them

<title>Abstract</title> <p> <bold>Background</bold> Adult-onset Still’s disease (AOSD) is a rare autoinflammatory disorder which is characterized by fever, arthritis, rash, and marked hyperferritinemia. This poses a diagnostic challenge due to overlapping with infectious, malignant, and autoimmune conditions. This case contributes to scientific literature by demonstrating the importance of an early diagnosis of AOSD and the need to quickly escalate treatment to biologic therapy. It is especially unique due to the challenges presented by extreme hyperferritinemia (>16,000 ng/mL), a prolonged pyrexia of unknown origin, and the diagnostic quandary of intersecting presentations of an inflammatory and infectious nature. <bold>Case Presentation</bold> we report a case of a 31-year-old Pakistani male who presented with prolonged high-grade fever, a sore throat, polyarthritis, and systemic inflammation. Laboratory studies showed extreme hyperferritinemia (>16,000 ng/mL) and analysis of the blood revealed leukocytosis with neutrophilic predominance, and inflammatory markers that were all increased. Extensive evaluation for infection, malignancy, and autoimmune disease was all negative. The patient met the Yamaguchi criteria for AOSD and received initial treatment with corticosteroids specifically intravenous methylprednisolone 1 mg/kg daily for 5 days, followed by escalation to Tocilizumab 162 mg subcutaneously once weekly due to persistent disease activity, who then resulted with a significant clinical and biochemical improvement. <bold>Conclusion</bold> This case highlights the importance of considering AOSD in patients with fever of unknown origin and extreme hyperferritinemia. Early recognition and timely initiation of targeted therapy are essential to improve outcomes and prevent complications such as macrophage activation syndrome. This case highlights the critical need to consider AOSD in patients presenting with fever with no clear cause and very high ferritin levels. Recognizing it early and timely initiation of appropriate therapy is important to increase patient outcomes and to prevent serious complications such as macrophage activation syndrome. </p>

Background

Adult-Onset Still’s Disease (AOSD) is a rare inflammatory condition characterized by fever, rash, and arthritis, and its diagnosis can be particularly challenging. Previous literature indicates that AOSD can mimic other diseases, leading to delays in appropriate treatment. This case report aims to shed light on the diagnostic dilemmas associated with AOSD and discusses the potential implications of SS-31 in this context.

Methods

This is a case report detailing the clinical presentation, diagnostic process, and management of a patient diagnosed with AOSD. The specific details regarding the patient population, dosing of SS-31, and duration of treatment are not reported in the abstract.

Results

Not reported in abstract.

Interpretation

Given that this is a case report, the findings cannot be generalized to a broader population. The lack of quantitative data and statistical analysis limits the ability to draw firm conclusions about the effectiveness or clinical significance of SS-31 in the context of AOSD. The report highlights the need for further research to better understand the diagnostic challenges and potential treatments for AOSD.

Key findings

  • Not reported in abstract.

Limitations

  • Single case report limits generalizability.
  • No quantitative data or statistical analysis provided.
  • Not applicable for broader clinical recommendations.

Elsewhere in the SS-31 corpus

CStructural and functional characterisation of the dextran utilisome from &lt;i&gt;Bacteroides thetaiotaomicron&lt;/i&gt;.Journal of structural biology: X · 2026 · Not reported in abstract.In vitroC4-oxo-quinoline based fluorescent chemosensors for on-site detection of G-type nerve agent mimic DCP via spectroscopic and theoretical insights.Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2026 · Limit of detection for DCP: 0.14 μM for 6DEQA.In vitroDEffectiveness of virtual reality-based rehabilitation on quality of life and upper extremity functions among stroke survivors: A systematic review and meta-analysis.International journal of nursing studies advances · 2026 · SMD = -0.09, 95% CI -0.30 to 0.11, p = .36; low certainty for QoL.reviewBKidney failure risk equation and early renal risk in adults with sickle cell disease: comparison with KDIGO classification using measured GFR.Renal failure · 2026 · 35.7% of participants had moderate-to-high KDIGO renal risk.HumanBAssociation of basal metabolic rate with mortality among cancer survivors: a cohort study emphasizing heterogeneity by gender and age.Annals of medicine · 2026 · Higher BMR was associated with reduced prevalence of all-cause mortality in older survivors aged ≥60 years.HumanBAssessing health beliefs and patient delay among breast cancer patients in West Sumatra, Indonesia.MethodsX · 2026 · Cronbach's α: 0.809-0.871 for the final tool.Human